Abstract
340
Objectives Sm-153-EDTMP therapy has been proven effective for pain palliation and benefits beyond mainly in osteoblastic recurrences. Data comparing osteoblastic vs. osteolytic recurrences concerning therapeutic response on are not available. We aimed to assess this question in female breast cancer patients.
Methods In 164 females suffering from breast cancer we assessed the response of recurrences judged by computer tomography as osteoblastic (BL), osteolytic (LY) or mixed (MI) showing up in bone scintigraphy to a single dose of 30 mCi Sm-153-EDTMP (1st treatment according to the Vienna-protocol). 116 females (70.03%) suffered from ductal, 37 (22.56%) from lobular, 10 (6.09%) from mixed and 1 (0.61%) from medullar cancer. Only patients with >1 up to 5 lesions and bone pain were involved.
Results Bone uptake did not differ between the groups and in patients on bisphosphonates. None of the examined parameters, in particular pain response, differed between BL-, LY- and MI-recurrences. No correlation of pain response and its duration vs. uptake, type, number and extent of lesions, waist circumference, adhesion molecules (AM) and histology was seen. Duration of pain palliation in responders was above 80% at 10 weeks in BL-, LY- and MI-recurrences. 61 females on statins (30.9%) exhibited a significantly (p < 0.01) more pronounced decrease in adhesion molecules (ICAM-1, VCAM-1, E-selectin) vs. non-users. No difference, however, was found between BL, LY and MI.
Conclusions These findings indicate a comparable response of BL-, LY- and MI-type breast cancer recurrences on Sm-153-EDTMP if they show up in bone-scintigraphy. The more pronounced decrease of tumor indicators (AM) in statin users irrespective of histology and type of recurrences confirms earlier results obtained with PSA in prostate cancer
Patients characteristics and results
* pain response (number / %)
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.